Real World Evidence RWE is becoming a crucial part of regulatory submissions as the pharmaceutical industry increasingly focuses on understanding how treatments perform outside controlled clinical trial environments. While randomized clinical trials remain the gold standard for proving efficacy, they do not always reflect real world patient populations, diverse treatment settings, or long term use. RWE fills these gaps by using data from electronic health records, insurance claims, patient registries, observational studies, and digital health platforms to provide a clearer view of real world effectiveness and safety.
Regulators such as the FDA and EMA have expanded their acceptance of RWE. RWE now supports decisions related to approvals, label expansions, post authorization monitoring, and benefit risk assessments. For RWE to be accepted, the evidence must meet strict expectations for relevance, reliability, transparency, and scientific rigor.
FDA Acceptance Criteria for RWE
Under the 21st Century Cures Act, the FDA recognizes RWE as a valuable source that can support various types of regulatory decisions.
Key Acceptance Requirements
Relevance
• Data must be directly related to the regulatory question.
• The patient population, clinical endpoints, and treatment conditions must be appropriate.
Reliability
• Data must be accurate, complete, and traceable.
• The study design should manage confounding factors and missing data using robust methods.
Transparency
• The full data process must be documented, including collection, preparation, linkage, and analysis.
• All steps should be reproducible and verifiable.
Methodological Rigor
• Statistical analysis plans should be defined in advance.
• Methods must be scientifically sound and aligned with regulatory expectations.
EMA Acceptance Criteria for RWE
The EMA has also increased its encouragement of RWE through initiatives such as the EU RWE Framework and Adaptive Pathways. These efforts promote continuous evidence generation throughout a product lifecycle.
Key Acceptance Requirements
Validated and Reliable Data Sources
• Acceptable sources include national registries, EHR systems, and verified medical databases.
Reflection of Real Clinical Practice
• Data should reflect routine medical care and include diverse patient groups.
Robust Analytical Methods
• Assumptions, analytical approaches, and sensitivity analyses should be clearly documented.
Complement to Clinical Trials
• RWE should strengthen benefit risk assessments and add value to trial findings.
Integration with Pharmacovigilance
• RWE should support ongoing monitoring of product safety and treatment outcomes.
Challenges in Using RWE
Although RWE offers strong advantages, it also presents notable challenges.
Data Heterogeneity
• Differences in coding systems and variable documentation practices create inconsistencies.
Bias and Confounding
• Observational data may include selection biases or unmeasured confounders.
Changing Regulatory Expectations
• Expectations continue to evolve, which requires continuous adaptation.
Quality Assurance Requirements
• Ensuring accurate, verifiable, and audit ready data is critical.
Best Practices for Including RWE in Submissions
To develop high quality RWE that is acceptable for submissions, organizations should follow structured practices.
Define the Objective Clearly
• Establish whether the RWE will support safety, effectiveness, label modifications, or post approval commitments.
Select High Quality Data Sources
• Use validated sources that capture consistent and comprehensive patient information.
Ensure Strong Methodology
• Apply statistical approaches that address confounding, bias, and missing data.
Prioritize Transparency
• Document every stage of the data life cycle, from collection to analysis.
Integrate RWE with Safety Monitoring
• Real world data can strengthen ongoing risk management activities.
Value of RWE for Post Market Surveillance
RWE plays an important role in post market evaluation and safety monitoring.
Key Benefits
• Early identification of adverse events across broad populations.
• Evaluation of treatment performance in diverse and underrepresented patient groups.
• Better understanding of long term effectiveness and risk.
• Support for continuous monitoring obligations throughout the product lifecycle.
Emerging Trends in RWE
The landscape of RWE is expanding rapidly due to technological growth and enhanced data availability.
• Growth in the use of digital health technologies such as wearable devices, mobile health applications, and remote monitoring tools.
• Increased adoption of artificial intelligence and machine learning for large scale data processing and pattern identification.
• Greater emphasis on patient reported outcomes, treatment satisfaction, and quality of life measures.
• Expanding collaboration between healthcare systems, data networks, and research organizations.
The Growing Influence of Digital Health Data
Digital health platforms generate real time, long term data that provide a deeper understanding of treatment impact. Continuous monitoring through connected devices offers insights into adherence, lifestyle influences, and daily patient experience. These data sources help identify trends that may not be visible in controlled trials.
Future Outlook for RWE
RWE is evolving into a core pillar of evidence generation across development, authorization, and post market stages. As expectations continue to strengthen, organizations that invest in high quality data systems, analytics, and transparent processes will be better positioned to produce credible real world insights. These efforts contribute to stronger decision making and a clearer understanding of patient outcomes over time.
How Quality and Vigilance Ltd Supports RWE
Quality and Vigilance Ltd helps organisations strengthen the quality, reliability, and usability of their Real-World Evidence programs through structured quality and vigilance practices.
Q&V Supports
- Ensuring real-world datasets are accurate, consistent, and audit-ready
- Validating data quality and completeness across different sources
- Maintaining clear and transparent documentation for data handling
- Supporting integration of RWE insights with ongoing safety and vigilance activities
- Developing quality frameworks, SOPs, and workflows that enhance evidence credibility
Contact Quality and Vigilance Ltd today to strengthen your RWE quality frameworks and ensure your real-world data programs are reliable, compliant, and inspection-ready.